MLL-AF4 t(4;11) Detection Kit
£681.00
geneMAP™ MLL-AF4 T(4;11) Detection Kit for Leukemia are intended for the quantitative detection of MLL-AF4, fusion transcripts in bone marrow or peripheral blood samples. The results obtained are intended to be used as an aid to monitor efficacy of treatment in patients undergoing therapy, and for minimal residual disease (MRD) follow-up to monitor disease relapse.
- Superior Analytical Sensitivity: Delivers a log4 reduction in detection sensitivity, enabling the identification of low levels of the MLL-AF4 fusion transcript.
- Fast and User-Friendly: Simplifies the testing process with one-step RT-qPCR technology, reducing the time to results.
- Multiplex PCR: Allows for accurate relative quantitation by comparing fusion transcripts against ABL1 gene expression, enhancing diagnostic precision.
- Instrument Compatibility: Designed for use with FAM and VIC/HEX dual-color real-time PCR instruments, ensuring versatility across laboratory settings.
- CE-IVD Certification: Meets European standards for in vitro diagnostic medical devices, ensuring the kit’s quality and reliability for clinical use.
Leukemia Diagnosis and Monitoring: Specifically targets the MLL-AF4 t(4;11) fusion gene for patients suspected of or diagnosed with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), playing a vital role in diagnosis, prognosis, and treatment monitoring.
- Technology: Employs one-step RT-qPCR with multiplex PCR for the detection and relative quantitation of the MLL-AF4 fusion transcript.
- Sensitivity: Features superior analytical sensitivity (log4 reduction) for detecting minimal levels of the target gene.
- Compatibility: Compatible with FAM and VIC/HEX dual-color real-time PCR instruments.
- Certification: Carries the CE-IVD mark, indicating compliance with EU regulations for in vitro diagnostic use.
Why Choose Clent
We strive to enable our customers to focus on the results of their work, rather than the tools they use. Need to speak with a member of our team? Get in touch today.
